For nearly eighty years, UCSF researchers and clinicians have been making breakthrough discoveries that have improved diabetes treatment and care for individuals with diabetes and their families.
UCSF pediatric endocrinologist and childhood obesity advocate and policy wonk Robert Lustig, MD is always willing to state his mind when it comes to sugar. Apparently people are listening. Ever since one of his local lectures entitled Sugar: The Bitter Truth was posted to YouTube last July, nearly 500,000 people have viewed this 90 minute video.
Even though dietary research projects are expensive to conduct, two physician researchers are pooling all of their resources to study the health benefits of following the Paleolithic or hunter-gatherer diet enjoyed by our ancestors.
Thanks to UCSF immunologists including Jeff Bluestone, PhD and Todd Brusko, PhD, a paradigm shift in thinking has occurred regarding the immune system’s role in type 1 diabetes. Previously, the goal was to suppress the immune system so insulin-producing beta cells weren’t destroyed.
Once again, the National Institute of Diabetes, Digestive & Kidney Diseases (NIDDK) has designated the UCSF Diabetes Center as a Diabetes Endocrinology Research Center (DERC), one of only 10 programs nationally to hold this prestigious rank.
A recent study involving a previously unstudied gene known as Rfx6 has shown how this gene is necessary for cells to differentiate into insulin-producing beta cells and other cells in the pancreas. This study was led by Michael German, MD, Diabetes Center Clinical Director and the Justine K. Schreyer Endowed Chair in Diabetes Research, and his colleague Constantin Polychronakos, MD, of McGill University.
It is hard to believe that a single patient can lead to new insights into autoimmune disease that merit publication in the New England Journal of Medicine (NEJM) . In a recent Letter to the Editor in the journal, our DC investigators report the case of a patient seen at the San Francisco General Hospital with symptoms of autoimmune polyglandular syndrome type 1 (APS1).
At the 7th World Congress on Insulin Resistance, researchers from the UCSF Diabetes Center received awards for their new research involving insulin resistance. Sinan Tanyolac, MD, a UCSF visiting scholar from Istanbul University who works closely with Diabetes Center researchers Ira Goldfine, MD and John Kane, MD , received first place for studies on the genetics of insulin resistance and type 2 diabetes.
Bay area employers are concerned about the rising incidence of diabetes in today's society. One of three families are affected by diabetes or at risk for contracting this disease. Providing education on diabetes prevention, warning signs, common myths, and general treatment options is vitally important to keep staff healthy and happy.
Since March is National Kidney Month and March 11, 2010 is officially World Kidney Day, we'd like to acknowledge the tremendous success of our UCSF Transplantation Program. UCSF has performed more kidney transplants than any other institution in the world — more than 8,300 since 1964 — and is the fifth largest center for living-donor kidney transplants in the country.
What better way to describe the clinical trial experience than through the eyes of a study participant? In this month's Popular Science magazine, journalist Catherine Price writes about her experience in a new-onset type 1 diabetes clinical study involving the monoclonal antibody anti-CD3.
It is hard to believe that we are just days away from the end of the decade, and nearly ten years since the founding of the UCSF Diabetes Center. I am grateful for the progress we continue to make toward preventing, treating and ultimately curing diabetes.
Within the last year, one of our type 1 diabetes clinical trials involving an effective cancer drug concluded. Results published in November 2009 in the New England Journal of Medicine (NEJM)shows that anti-CD20 (FDA approved and marketed as Rituxan) has been shown to be effective in new onset diabetes by slowing down the progression of the disease.